{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:53:10Z","timestamp":1795085590624,"version":"4.10.2"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute hepatic porphyrias (AHPs) are a family of four rare genetic diseases resulting from a deficiency in one of the enzymes involved in heme biosynthesis. AHP patients can experience potentially life-threatening acute attacks, characterized by severe abdominal pain, along with other signs and symptoms including nausea, mental confusion, hyponatraemia, hypertension, tachycardia and muscle weakness. Some patients also experience chronic manifestations and long-term complications, such as chronic pain syndrome, neuropathy and porphyria-associated kidney disease. Most symptomatic patients have only a few attacks in their lifetime; nevertheless, some experience frequent attacks that result in ongoing symptoms and a significant negative impact on their quality of life (QoL). Initial diagnosis of AHP can be made with a test for urinary porphobilinogen, <jats:inline-formula><jats:alternatives><jats:tex-math>$$\\delta$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03b4<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula>-aminolaevulinic acid and porphyrins using a single random (spot) sample. However, diagnosis is frequently missed or delayed, often for years, because the clinical symptoms of AHP are non-specific and mimic other more common disorders. Delayed diagnosis is of concern as some commonly used medications can trigger or exacerbate acute attacks, and untreated attacks can become severe, potentially leading to permanent neurological damage or fatality. Other attack triggers include hormonal fluctuations in women, stress, alcohol and low-calorie diets, which should be avoided in patients where possible. For the management of attacks, intravenous hemin is approved, whereas new therapeutic approaches are currently being investigated as a baseline therapy for prevention of attacks and improvement of QoL. Among these, a novel siRNA-based agent, givosiran, has shown very promising results in a recently concluded Phase III trial and has been approved for the management of AHPs. Here, we propose a challenging case study-with a very unusual pediatric onset of variegate porphyria-as a starting point to summarize the main clinical aspects (namely, clinical manifestations, diagnostic challenges, and therapeutic management) of AHPs, with a focus on the latest therapeutic innovations.<\/jats:p>","DOI":"10.1186\/s13023-022-02314-9","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T14:09:03Z","timestamp":1649340543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives"],"prefix":"10.1186","volume":"17","author":[{"given":"Matteo","family":"Marcacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cuoghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Pietrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-1914","authenticated-orcid":false,"given":"Paolo","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"issue":"9718","key":"2314_CR1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","volume":"375","author":"H Puy","year":"2010","unstructured":"Puy H, Gouya L, Deybach J-C. Porphyrias. The Lancet. 2010;375(9718):924\u201337.","journal-title":"The Lancet"},{"issue":"23","key":"2314_CR2","first-page":"4496","volume":"120","author":"M Balwani","year":"2012","unstructured":"Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood J Am Soc Hematol. 2012;120(23):4496\u2013504.","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"2314_CR3","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30936","volume":"71","author":"L Gouya","year":"2020","unstructured":"Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, St\u00f6lzel U, Phillips JD, Kauppinen R, Langendonk JG, Desnick RJ, et al. Explore: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks. Hepatology. 2020;71(5):1546\u201358.","journal-title":"Hepatology"},{"issue":"4","key":"2314_CR4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/hep.29313","volume":"66","author":"M Balwani","year":"2017","unstructured":"Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, Phillips JD, Desnick RJ. Of the rare diseases clinical research network P.C.: acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017;66(4):1314\u201322.","journal-title":"Hepatology"},{"issue":"2","key":"2314_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1297","volume":"3","author":"B Wang","year":"2019","unstructured":"Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyrias: review and recent progress. Hepatol Commun. 2019;3(2):193\u2013206.","journal-title":"Hepatol Commun"},{"issue":"3","key":"2314_CR6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2019.07.002","volume":"128","author":"KE Anderson","year":"2019","unstructured":"Anderson KE. Acute hepatic porphyrias: current diagnosis & management. Mol Genet Metab. 2019;128(3):219\u201327.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2314_CR7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2019.03.002","volume":"128","author":"HL Bonkovsky","year":"2019","unstructured":"Bonkovsky HL, Dixon N, Rudnick S. Pathogenesis and clinical features of the acute hepatic porphyrias (ahps). Mol Genet Metab. 2019;128(3):213\u20138.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2314_CR8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/metabo4040977","volume":"4","author":"S Besur","year":"2014","unstructured":"Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4(4):977\u20131006.","journal-title":"Metabolites"},{"issue":"12","key":"2314_CR9","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3390\/diagnostics11122205","volume":"11","author":"A Ricci","year":"2021","unstructured":"Ricci A, Di Pierro E, Marcacci M, Ventura P. Mechanisms of neuronal damage in acute hepatic porphyrias. Diagnostics. 2021;11(12):2205.","journal-title":"Diagnostics"},{"issue":"3","key":"2314_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.amjmed.2014.10.026","volume":"128","author":"DM Bissell","year":"2015","unstructured":"Bissell DM, Lai JC, Meister RK, Blanc PD. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med. 2015;128(3):313\u20137.","journal-title":"Am J Med"},{"issue":"1","key":"2314_CR11","first-page":"17","volume":"86","author":"V-MS Ramanujam","year":"2015","unstructured":"Ramanujam V-MS, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc Hum Genet. 2015;86(1):17\u201320.","journal-title":"Curr Protoc Hum Genet"},{"issue":"5","key":"2314_CR12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","volume":"36","author":"G Elder","year":"2013","unstructured":"Elder G, Harper P, Badminton M, Sandberg S, Deybach J-C. The incidence of inherited porphyrias in europe. J Inherit Metab Dis. 2013;36(5):849\u201357.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2314_CR13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.12750","volume":"284","author":"C Schmitt","year":"2018","unstructured":"Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, Letteron P, Paradis V, Wahlin S, Sandberg S, et al. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver. J Int Med. 2018;284(1):78\u201391.","journal-title":"J Int Med"},{"issue":"2","key":"2314_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1005313024076","volume":"20","author":"G Elder","year":"1997","unstructured":"Elder G. Hepatic porphyrias in children. J Inherit Metab Dis. 1997;20(2):237\u201346.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2314_CR15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/088307388600100106","volume":"1","author":"PW Kaplan","year":"1986","unstructured":"Kaplan PW, Lewis DV. Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature. J Child Neurol. 1986;1(1):38\u201345.","journal-title":"J Child Neurol"},{"issue":"5","key":"2314_CR16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1651-2227.2003.tb02507.x","volume":"92","author":"J Hultdin","year":"2003","unstructured":"Hultdin J, Schmauch A, Wikberg A, Dahlquist G, Andersson C. Acute intermittent porphyria in childhood: a population-based study. Acta Paediatr. 2003;92(5):562\u20138.","journal-title":"Acta Paediatr"},{"issue":"195","key":"2314_CR17","first-page":"2","volume":"8","author":"E Pierro","year":"2017","unstructured":"Pierro E, Granata F, Rosafio C, Marchini S, Guerra A, et al. Acute intermittent porphyria in a child with severe neuropathy. J Blood Lymph. 2017;8(195):2.","journal-title":"J Blood Lymph"},{"key":"2314_CR18","doi-asserted-by":"publisher","unstructured":"Fatima SA, Jurair H, Abbas Q, Rehman AJ. Paediatric porphyria and human hemin: a treatment challenge in a lower middle income country. BMJ Case Rep CP 2020; 13(1) . https:\/\/doi.org\/10.1136\/bcr-2019-232236. https:\/\/casereports.bmj.com\/content\/13\/1\/e232236.full.pdf","DOI":"10.1136\/bcr-2019-232236"},{"issue":"2","key":"2314_CR19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2796.2003.01172.x","volume":"254","author":"C Andersson","year":"2003","unstructured":"Andersson C, Innala E, B\u00e4ckstr\u00f6m T. Acute intermittent porphyria in women. clinical expression, use and experience of exogenous sex hormones. a population-based study in northern sweden. J Int Med. 2003;254(2):176\u201383.","journal-title":"J Int Med"},{"issue":"11","key":"2314_CR20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/humu.23067","volume":"37","author":"B Chen","year":"2016","unstructured":"Chen B, Solis-Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, Balwani M, Doheny D, Peter I, Chen R, et al. Acute intermittent porphyria: predicted pathogenicity of hmbs variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat. 2016;37(11):1215\u201322.","journal-title":"Hum Mutat"},{"issue":"7","key":"2314_CR21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddy030","volume":"27","author":"H Lenglet","year":"2018","unstructured":"Lenglet H, Schmitt C, Grange T, Manceau H, Karboul N, Bouchet-Crivat F, Robreau A-M, Nicolas G, Lamoril J, Simonin S, et al. From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria. Hum Mol Genet. 2018;27(7):1164\u201373.","journal-title":"Hum Mol Genet"},{"key":"2314_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/TACG.S48605","volume":"8","author":"E Pischik","year":"2015","unstructured":"Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201.","journal-title":"Appl Clin Genet"},{"issue":"12","key":"2314_CR23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","volume":"127","author":"HL Bonkovsky","year":"2014","unstructured":"Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, Phillips JD, Naik H, Peter I, Baillargeon G, et al. Acute porphyrias in the usa: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233\u201341.","journal-title":"Am J Med"},{"issue":"3","key":"2314_CR24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2019.10.011","volume":"128","author":"DA Jaramillo-Calle","year":"2019","unstructured":"Jaramillo-Calle DA, Solano JM, Rabinstein AA, Bonkovsky HL. Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction. Mol Genet Metab. 2019;128(3):242\u201353.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2314_CR25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","volume":"142","author":"KE Anderson","year":"2005","unstructured":"Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Int Med. 2005;142(6):439\u201350.","journal-title":"Ann Int Med"},{"issue":"5","key":"2314_CR26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40271-018-0319-3","volume":"11","author":"A Simon","year":"2018","unstructured":"Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, Howe DL, Hungate JR, Kim JB, Agarwal S, et al. Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations. Patient Patient-Centered Outcomes Res. 2018;11(5):527\u201337.","journal-title":"Patient Patient-Centered Outcomes Res"},{"issue":"4","key":"2314_CR27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/bjh.14459","volume":"176","author":"PE Stein","year":"2017","unstructured":"Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2017;176(4):527\u201338.","journal-title":"Br J Haematol"},{"key":"2314_CR28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/8904_2015_458","volume":"25","author":"B Willandt","year":"2015","unstructured":"Willandt B, Langendonk JG, Biermann K, Meersseman W, D\u2019Heygere F, George C, Verslype C, Monbaliu D, Cassiman D. Liver fibrosis associated with iron accumulation due to long-term heme-arginate treatment in acute intermittent porphyria: a case series. JIMD Rep. 2015;25:77\u201381.","journal-title":"JIMD Rep"},{"issue":"3","key":"2314_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/joim.12646","volume":"282","author":"C Baravelli","year":"2017","unstructured":"Baravelli C, Sandberg S, Aarsand A, Nilsen R, Toll\u00e5nes M. Acute hepatic porphyria and cancer risk: a nationwide cohort study. J Int Med. 2017;282(3):229\u201340.","journal-title":"J Int Med"},{"issue":"4","key":"2314_CR30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2796.1996.21847000.x","volume":"240","author":"C Andersson","year":"1996","unstructured":"Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Int Med. 1996;240(4):195\u2013201.","journal-title":"J Int Med"},{"issue":"2","key":"2314_CR31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ckj\/sfx146","volume":"11","author":"N Pallet","year":"2018","unstructured":"Pallet N, Karras A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. Clin Kidney J. 2018;11(2):191\u20137.","journal-title":"Clin Kidney J"},{"issue":"12","key":"2314_CR32","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.3390\/diagnostics11122324","volume":"11","author":"A Ricci","year":"2021","unstructured":"Ricci A, Guida CC, Manzini P, Cuoghi C, Ventura P. Kidney involvement in acute hepatic porphyrias: pathophysiology and diagnostic implications. Diagnostics. 2021;11(12):2324.","journal-title":"Diagnostics"},{"issue":"1","key":"2314_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11920-018-0867-1","volume":"20","author":"L Duque-Serrano","year":"2018","unstructured":"Duque-Serrano L, Patarroyo-Rodriguez L, Gotlib D, Molano-Eslava JC. Psychiatric aspects of acute porphyria: a comprehensive review. Curr Psychiatry Rep. 2018;20(1):1\u20137.","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"2314_CR34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2016.08.006","volume":"119","author":"H Naik","year":"2016","unstructured":"Naik H, Stoecker M, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study. Mol Genet Metab. 2016;119(3):278\u201383.","journal-title":"Mol Genet Metab"},{"key":"2314_CR35","unstructured":"American Porphyria Foundation. The voice of the patient: patient-focused drug development meeting - acute porphyrias. 2017. https:\/\/www.fda.gov\/media\/130386\/download (accessed: 4 January 2022)"},{"issue":"5","key":"2314_CR36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10545-018-0178-z","volume":"41","author":"RA Neeleman","year":"2018","unstructured":"Neeleman RA, Wagenmakers MA, Koole-Lesuis RH, Mijnhout GS, Wilson JP, Friesema EC, Langendonk JG. Medical and financial burden of acute intermittent porphyria. J Inherited Metab Dis. 2018;41(5):809\u201317.","journal-title":"J Inherited Metab Dis"},{"key":"2314_CR37","doi-asserted-by":"crossref","unstructured":"Gouya L, Bloomer J, Balwani M, Bissell D, Rees D, St\u00f6lzel U, Phillips J, Kauppinen R, Langendonk J, Desnick R, Deybach J. An analysis of healthcare utilization and costs associated with patients with acute hepatic porphyrias (ahp) with recurrent attacks in explore: a prospective, multinational natural history study of patients with ahp. Int Congress Porphyria and Porphyrias (ICPP); 25\u201328 June 2017; Paris, France","DOI":"10.1016\/j.jval.2018.04.856"},{"issue":"6","key":"2314_CR38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ejim.2014.03.011","volume":"25","author":"P Ventura","year":"2014","unstructured":"Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E, Porfiria GI. A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias. Eur J Int Med. 2014;25(6):497\u2013505.","journal-title":"Eur J Int Med"},{"key":"2314_CR39","doi-asserted-by":"crossref","unstructured":"Bissell DM. The porphyrias. Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease. 2015;731\u2013749.","DOI":"10.1016\/B978-0-12-410529-4.00066-8"},{"issue":"3","key":"2314_CR40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7861\/clinmedicine.12-3-293","volume":"12","author":"P Stein","year":"2012","unstructured":"Stein P, Badminton MN, Barth J, Rees D, Sarkany R, Stewart M, Cox T. Acute intermittent porphyria: fatal complications of treatment. Clin Med. 2012;12(3):293.","journal-title":"Clin Med"},{"issue":"2","key":"2314_CR41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0004563216667965","volume":"54","author":"J Woolf","year":"2017","unstructured":"Woolf J, Marsden JT, Degg T, Whatley S, Reed P, Brazil N, Stewart MF, Badminton M. Best practice guidelines on first-line laboratory testing for porphyria. Ann Clin Biochem. 2017;54(2):188\u201398.","journal-title":"Ann Clin Biochem"},{"issue":"7","key":"2314_CR42","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1373\/clinchem.2008.122564","volume":"55","author":"SD Whatley","year":"2009","unstructured":"Whatley SD, Mason NG, Woolf JR, Newcombe RG, Elder GH, Badminton MN. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the hmbs, cpox, or ppox gene. Clin Chem. 2009;55(7):1406\u201314.","journal-title":"Clin Chem"},{"key":"2314_CR43","unstructured":"Orphan Europe. Summary of product characteristics: Normosang 25 mg\/ml, concentrate for solution for infusion (2007). https:\/\/www.mhlw.go.jp\/shingi\/2008\/03\/dl\/s0326-10n.pdf (accessed 4 January 2022.)"},{"key":"2314_CR44","doi-asserted-by":"crossref","unstructured":"Open-label study of hemin for acute porphyria. Clinical practice implications. The American Journal of Medicine. 2006;119(9):801\u201318016.","DOI":"10.1016\/j.amjmed.2006.05.026"},{"key":"2314_CR45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/8904_2015_411","volume":"22","author":"JT Marsden","year":"2015","unstructured":"Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, Barth JH, Stewart MF, Rees DC. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep. 2015;22:57\u201365.","journal-title":"JIMD Rep"},{"key":"2314_CR46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2017_2","volume":"36","author":"D Schulenburg-Brand","year":"2017","unstructured":"Schulenburg-Brand D, Gardiner T, Guppy S, Rees DC, Stein P, Barth J, Stewart MF, Badminton M. An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the united kingdom. JIMD Rep. 2017;36:99\u2013107.","journal-title":"JIMD Rep"},{"issue":"1","key":"2314_CR47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00016340903390729","volume":"89","author":"E Innala","year":"2010","unstructured":"Innala E, B\u00e4ckstr\u00f6m T, Bixo M, Andersson C. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand. 2010;89(1):95\u2013100.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"2314_CR48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/lt.22345","volume":"18","author":"JK Dowman","year":"2012","unstructured":"Dowman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, Newsome PN, Selection UL, Party AW. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl. 2012;18(2):195\u2013200.","journal-title":"Liver Transpl"},{"issue":"3","key":"2314_CR49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Givosiran: first approval. Drugs. 2020;80(3):335\u20139.","journal-title":"Drugs"},{"key":"2314_CR50","unstructured":"Alnylam Pharmaceuticals. Alnylam announces approval of GIVLAARI\u00ae (givosiran) in Brazil for the treatment of acute hepatic porphyria (AHP) in adults (press release) Sao Paulo, Brazil 2020. https:\/\/investors.alnylam.com\/sites\/default\/files\/GIVLAARI-Brazil-Approval-Press-Release.pdf"},{"key":"2314_CR51","unstructured":"European Medicines\u00a0Agency EMA. Givlaari (summary of product characteristics) 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/givlaari-epar-product-information_en.pdf"},{"key":"2314_CR52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/mtna.2015.36","volume":"4","author":"A Chan","year":"2015","unstructured":"Chan A, Liebow A, Yasuda M, Gan L, Racie T, Maier M, Kuchimanchi S, Foster D, Milstein S, Charisse K, et al. Preclinical development of a subcutaneous alas1 rnai therapeutic for treatment of hepatic porphyrias using circulating rna quantification. Mol Therapy Nucl Acids. 2015;4:263.","journal-title":"Mol Therapy Nucl Acids"},{"issue":"24","key":"2314_CR53","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, Peir\u00f3 PA, Rees DC, St\u00f6lzel U, Bissell DM, Bonkovsky HL, Windyga J, Anderson KE, et al. Phase 3 trial of rnai therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289\u2013301.","journal-title":"N Engl J Med"},{"key":"2314_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15090","author":"P Ventura","year":"2022","unstructured":"Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peir\u00f3 P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E. ENVISION Investigators: Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 envision study. Liver Int. 2022. https:\/\/doi.org\/10.1111\/liv.15090.","journal-title":"Liver Int"},{"key":"2314_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12391","author":"J To-Figueras","year":"2021","unstructured":"To-Figueras J, Wijngaard R, Garc\u00eda-Villoria J, Aarsand AK, Aguilera P, Deulofeu R, Brunet M, Gomez-Gomez A, Pozo OJ, Sandberg S. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. J Inherit Metab Dis. 2021. https:\/\/doi.org\/10.1002\/jimd.12391.","journal-title":"J Inherit Metab Dis"},{"key":"2314_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04547-3","author":"PE Petrides","year":"2021","unstructured":"Petrides PE, Klein M, Schuhmann E, Torkler H, Molitor B, Loehr C, Obermeier Z, Beykirch MK. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit? Ann Hematol. 2021. https:\/\/doi.org\/10.1007\/s00277-021-04547-3.","journal-title":"Ann Hematol"},{"key":"2314_CR57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejim.2021.06.023","volume":"92","author":"A Ricci","year":"2021","unstructured":"Ricci A, Marcacci M, Cuoghi C, Pietrangelo A, Ventura P. Hyperhomocysteinemia in patients with acute porphyrias: a possible effect of alas1 modulation by sirnam therapy and its control by vitamin supplementation. Eur J Int Med. 2021;92:121\u20133.","journal-title":"Eur J Int Med"},{"issue":"7","key":"2314_CR58","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ekir.2021.04.004","volume":"6","author":"H Lazareth","year":"2021","unstructured":"Lazareth H, Poli A, Bignon Y, Mirmiran A, Rabant M, Cohen R, Schmitt C, Puy H, Karras A, Gouya L, Pallet N. Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyria. Kidney Int Rep. 2021;6(7):1904\u201311. https:\/\/doi.org\/10.1016\/j.ekir.2021.04.004.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"2314_CR59","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","volume":"65","author":"D D\u2019Avola","year":"2016","unstructured":"D\u2019Avola D, L\u00f3pez-Franco E, Sangro B, Pa\u00f1eda A, Grossios N, Gil-Farina I, Benito A, Twisk J, Paz M, Ruiz J, et al. Phase i open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol. 2016;65(4):776\u201383.","journal-title":"J Hepatol"},{"issue":"4","key":"2314_CR60","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1089\/hum.2017.056","volume":"29","author":"I Serrano-Mendioroz","year":"2018","unstructured":"Serrano-Mendioroz I, Sampedro A, Alegre M, Enriquezde Salamanca R, Berraondo P, Fontanellas A. An inducible promoter responsive to different porphyrinogenic stimuli improves gene therapy vectors for acute intermittent porphyria. Hum Gene Ther. 2018;29(4):480\u201391.","journal-title":"Hum Gene Ther"},{"issue":"12","key":"2314_CR61","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","volume":"24","author":"L Jiang","year":"2018","unstructured":"Jiang L, Berraondo P, Jeric\u00f3 D, Guey LT, Sampedro A, Frassetto A, Benenato KE, Burke K, Santamar\u00eda E, Alegre M, et al. Systemic messenger rna as an etiological treatment for acute intermittent porphyria. Nat Med. 2018;24(12):1899\u2013909.","journal-title":"Nat Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02314-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T14:10:04Z","timestamp":1649340604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02314-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2314"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02314-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The patient (who at the time of writing has reached legal age) has provided written consent for publication of the Case Study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient (who at the time of writing has reached legal age) has provided written consent for publication of the Case Study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Paolo Ventura and Matteo Marcacci \u2013 received grants for consulting and lectures from Alnylam Pharmaceuticals and Recordati\u2013Rare Diseases","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}